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coronary artery disease.
In acute heart failure, and especially in cardiogenic shock related to ischemic conditions, vasopressors and
inotropes are used. However, both pathophysiological considerations and available clinical data suggest that
these treatments may have disadvantageous effects. The inodilator levosimendan offers potential beneﬁts due
to a range of distinct effects including positive inotropy, restoration of ventriculo-arterial coupling, increases in
tissue perfusion, and anti-stunning and anti-inﬂammatory effects. In clinical trials levosimendan improves symp-
toms, cardiac function, hemodynamics, and end-organ function. Adverse effects are generally less common than
with other inotropic and vasoactive therapies, with the notable exception of hypotension. The decision to use
levosimendan, in terms of timing and dosing, is inﬂuenced by the presence of pulmonary congestion, and
blood pressure measurements. Levosimendan should be preferred over adrenergic inotropes as a ﬁrst line ther-
apy for all ACS-AHF patients who are under beta-blockade and/or when urinary output is insufﬁcient after di-
uretics. Levosimendan can be used alone or in combination with other inotropic or vasopressor agents, but
requires monitoring due to the risk of hypotension.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).liKeywords:
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Levosimendan1. Introduction
Acute coronary syndrome (ACS) is one of themain precipitating fac-
tors of acute heart failure (AHF) [1], usually in the context of extensive
myocardial ischemia, myocardial dysfunction and injury, and arrhyth-
mia. It can lead to the development of de novo AHF or worsening of
chronic heart failure [2]. AHF, in turn, can deteriorate into cardiogenic
shock (CS). It has been estimated that 15–28% of patients with ACS ex-
perience signs and symptoms of AHF. Cardiogenic shock complicating
acute myocardial infarction (AMI) occurs in 5–15% [3].
Levosimendan is a calcium sensitizer and ATP-dependent potassium
channel opener [4], developed for the treatment of acute decompensat-
ed heart failure [5], with a solid evidence of efﬁcacy and safety [6]. This
inodilator, used in clinical practice since year 2000, has been tested in
the early phases of development in a randomized, placebo-controlled,
double-blind safety and efﬁcacy study in patients with left ventricular
failure due to an AMI [7]. In the last 15 years some additional evidence
has been collected on the use of levosimendan in AHF and CS complicat-
ing ACS. In this review and opinion paper the authors analyze the
existing data and clinical experience, and give some recommendations
on the use of levosimendan in AHF and CS related to ischemic
conditions.
2. Methods
A panel of 34 experts in the ﬁeld of cardiology, intensive care medi-
cine, internal medicine, and cardiovascular pharmacology from 20
European countries (Austria, Belgium, Czech Republic, Denmark,
Estonia, Finland, France, Germany, Greece, Hungary, Italy, Norway,
Poland, Portugal, Russia, Slovenia, Spain, Sweden, the United Kingdom,
and Ukraine) convened inMunich on January 22nd, 2016 to review sys-
tematically the existing data on the use of levosimendan in AHF and CS
complicating ACS. Pertinent studies were independently searched in
BioMedCentral, PubMed, and Embase (updated January 7, 2016) by
three trained investigators. The full search strategy was aimed to
include any randomized study ever performed with levosimendan in
the relevant clinical setting. The retrieved literature was available for
consultation by all the meeting invitees for two weeks before the meet-
ing. During the meeting the group discussed and reached a consensus
on the epidemiology and outcome of AHF and CS complicating ACS,
and – in general – on the pathophysiology of myocardial ischemia.
Furthermore, the panel reached a consensus on some recommendations
regarding the use of levosimendan, based on existing literature and
clinical experience. The objectives of this opinion paper, in line with
the overall vision of the European Society of Cardiology on guidelines
[8], are to enhance the appropriateness of practice, and improve quality
of cardiovascular care and patient outcomes.3. Epidemiology and outcome
3.1. Acute heart failure complicating ACS
AHF is frequently complicating ACS especially when large infarction,
extensive ischemic area with stunning or mitral regurgitation, and
arrhythmias are present [9]. In the EHFS II study, 42% of the de novo
AHF was due to ACS [9]. In a recent prospective multicenter study, CS
and pulmonary edemawere found to bemore common in ACS–AHF pa-
tients than in AHF patients without concomitant ACS [10]. Accordingly,
the ACS–AHF patients were found to have markedly higher short-term
mortality rates, with an almost two-fold 30-day mortality (13% vs. 8%;
p = 0.03). ACS was shown to be an independent predictor of 30-day
mortality in the HF population. Interestingly, however, the 5-year
mortality rates did not differ (59% vs. 61%; p = 0.80). In addition,
ACS–AHF prolongs hospitalization and requires more costly treatment
in intensive care.
Overall, the incidence of AHF as a complication of ACS, as well as the
correspondingmortality, has been decreasing over the last years. Based
on the data derived from the SWEDEHEART registry that included
199,851 patients admitted with myocardial infarction between 1996
and 2008 [11], the incidence of HF declined from 46% to 28%
(p b 0.001). This decrease was more pronounced in patients with ST-
segment elevation myocardial infarction (STEMI) than in those with
non-ST-segment elevation myocardial infarction (NSTEMI). The de-
crease in HF can probably be explained bymore frequent use of primary
PCI,which secures early reperfusion in patientswith STEMI and, thereby,
salvages jeopardized myocardium. Also, an increased use of evidence
based pharmacological treatment preventing remodeling may contrib-
ute. Finally, the more frequent detection of minor AMI with high-
sensitivity troponin testing may lower the estimated HF risk, since the
precipitation of AHF depends on the size of injury or ischemic area.
At all events, HF is still a signiﬁcant complication that affects a
substantial proportion of patients and worsens outcomes. Risk factors
for the development of AHF during a hospital stay due to ACS, according
tomultivariate analysis based on the data obtained in SWEDEHEART, in-
clude advanced age, female gender, history of AMI, diabetes mellitus,
hypertension, and history of chronic HF.
3.2. Cardiogenic shock complicating ACS
The CardShock Study identiﬁed ischemic causes as the principal
etiology of CS (81%) [12]. As opposed to AHF, the incidence of CS upon
admission has remained fairly stable over time, although the incidence
during hospital stay has decreased [13]. While CS has become less
common in STEMI, this is not the case for patients with non-ST-
segment elevation ACS [13]. Although the prognosis of CS has been
152 M.S. Nieminen et al. / International Journal of Cardiology 218 (2016) 150–157slowly improving over the past few decades [14,15], themortality is still
high, and remains between 40% and 50% despite advances in early
revascularization and the implementation of new drugs [3]. Patients
developing CS due to ischemic heart disease show signiﬁcantly worse
outcomes than those with non-ischemic causes [12]. Among patients
with ischemic CS, more than 70% present with multi-vessel disease
and this group faces an increased risk of mortality as compared to
those with single-vessel disease [3]. Other factors associated with high
mortality in CS are advanced age, history of previous myocardial
infarction or coronary artery bypass grafting, anoxic brain damage or
confusion, decreases in left-ventricular ejection fraction (LVEF), cardiac
index (CI) cardiac output and systolic blood pressure, need for vasopres-
sor support, deterioration in renal function, and elevated serum lactate
levels [12]. Prior CPR is also an important factor.
A patient who presents with CS should be triaged to a fast track or
urgent care setting, with the aim of either maintaining perfusion to
prevent organ dysfunction, or trying to retain organ dysfunction in a re-
versible state [16]. It should be immediately ascertained whether the
patient is hemodynamically stable or unstable. In a non-responding pa-
tient, the use of mechanical circulatory support system or extracorpore-
al membrane oxygenation (ECMO) should be considered if it becomes
obvious that the patient is not going to be stable under medication
alone. The management of patients who develop CS in the course of
their hospital stay is even more challenging than that of patients pre-
senting with CS already at admission, and they must not be overlooked.
In fact, there has been nomajor breakthrough in the management of CS
since the 1990s. There is still a need to improve understanding, risk
stratiﬁcation, and management of CS.
3.3. Pathophysiology following myocardial ischemia
Within hours, ischemia of the myocardium may induce AHF due to
increased wall stiffness, stunning and mechanical complications of in-
farction and reduced contractility (Fig. 1) [17]. The subsequent changes
in hemodynamics occur within the ﬁrst 24–48 h. Recovery is delayed in
stunning or hibernatingmyocardium (2–4 d). Due to the rapid develop-
ment of HF, the pulmonary vasculature is frequently not able to adapt
promptly. While the right ventricle might function normally, impairedFig. 1. Factors contributing to heart failurleft ventricular function and hemodynamic overload results in back-
ward failure with pulmonary congestion/edema. Mitochondrial dys-
function may contribute to the progression of cardiac ischemic injury,
especially at the onset of reperfusion, because defective oxidative phos-
phorylation in the presence of an excessive energy demand is likely to
trigger irreversible damage of cardiomyocytes [18]. Therefore, recovery
is greatly accelerated if the worsening condition is treated without
delay. According to the Forrester classiﬁcation [19], the most challeng-
ingHF patients are thosewho show both congestion and hypoperfusion
(“wet and cold”).
In terms of pathophysiology, profound depression of myocardial
contractility leads to CS, resulting in a vicious spiral of reduced cardiac
output (CO), low blood pressure, impaired coronary perfusion, and
further concomitant reductions in contractility and CO. Also, an acute
deterioration in the diastolic function may contribute to further
derangement of ventricular function and congestion. The classical para-
digm predicts that compensatory systemic vasoconstriction occurs in
response to this, i.e. over activation of adrenergic and RAAS reﬂex-
mechanisms causing increases in vascular resistance, but this is not al-
ways the case [20]. Impaired hemodynamic capability is also due to
changes in ventricular and arterial elastance [21]. Under normal condi-
tions ventricular and arterial elastances show approximately equal
slopes, providing hemodynamic equilibrium to occur at the lowest en-
ergy cost [22]. In a failing condition, however, reductions in the contrac-
tility and/or increases in the arterial elastance lead to ventriculo-arterial
uncoupling and increasedmyocardial oxygen consumption. The admin-
istration of vasopressors worsen this problem by enhancing peripheral
vasoconstriction and, thereby, further worsening ventriculo-arterial
coupling. Overtime inﬂammation induced vasodilation will decrease
organ perfusion and will result in multiorgan dysfunction.
4. Current practice and evidence-based guidelines
At present, speciﬁc consensus and international guidelines on the
comprehensive pharmacological and non-pharmacological treatments
of ACS patients with HF are not available. HF guidelines commonly ex-
clude ACS patients, while ACS guidelines tend to focus predominantly
on invasive therapies. This lack of treatment guidelines can be explainede in acute coronary syndromes [17].
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excluded patients with AHF/CS due to ACS. According to the only avail-
able guideline in Europe (theGerman–Austrian S3 Guideline on diagno-
sis, monitoring and treatment of CS due to myocardial infarction [23]),
there is a lack of evidence for all recommended therapeutic strategies.
Likewise, in their review of pharmacologic therapies for acute CS,
Nativi-Nicolau et al. [24] found that reliable information regarding com-
parative efﬁcacy of individual agents is insufﬁcient. Moreover, mortality
data are not available or uncertain. The authors concluded that the use
of inotropes and vasopressors and diuretics should be limited to the
bridging of patients to recovery, mechanical circulatory support or
heart transplantation. A Cochrane analysis on inotropic agents and va-
sodilator strategies for AMI complicated by shock or low-cardiac-
output syndrome [25] states that there is no robust or convincing data
to support a speciﬁc inotropic or vasodilatory therapy as a superior
strategy to other therapies used to reducemortality in hemodynamically
unstable patients.
Guidelines recommend the administration of adrenergic agents if
necessary for maintaining adequate circulation, but recommend also
that these drugs should be given at as low dose and for as short duration
as possible to prevent side effects.
4.1. Inotropes in patients with ACS and CS
Inotropic drugs are indeed used as ﬁrst-line treatment, without or
with vasopressors in patients with CS related to ACS [26]. The adminis-
tration of these drugs requires continuous monitoring of hemodynamic
parameters and, in a state of hypoperfusion, ﬂuid compensation under
invasive measurement of blood pressure and possibly CO. Inotropic
agents should be given for a limited period of time, and it is advisable
to deﬁne criteria for planned weaning at the time of initiation of treat-
ment. As soon as a stable condition has been achieved, weaning off
should be considered. Mechanical circulatory support should be consid-
ered as soon it becomes clear that hemodynamic stability with pre-
served endorgan function cannot bemaintainedwithmedication alone.
4.2. Vasoconstrictors/inopressors in patients with ACS and CS
Vasopressors and inotropes are a mainstay of treatment of patients
with CS. Vasopressors are frequently used alone in an attempt to restore
blood pressure. Several studies suggest, however, that this approach is
not advisable since it may inﬂict harm. An analysis combining three
data bases [27] showed that themortalitywas higher in patients treated
with vasopressors alone than in those receiving combinations of vaso-
pressors and inotropes. This effect was independent of the underlying
disease and the database used.
These results are echoed in other studies, such as an analysis of
approximately 5000 patients with AHF including CS in the ALARM
database [28]. In this study, the use of epinephrine and norepinephrine
predicted the poorest outcomes.
Overall, these data are a strong signal indicating that monotherapy
with vasopressors and/or inopressors should be avoided in the treat-
ment of the failing heart, as the associated increase in LV afterload
imposes a burden on the ischemic myocardium. In contrast, these path-
ophysiological considerations render the use of an inodilator more
suitable.
Of course, mechanical circulatory support is an important part of the
treatment of CS. Choices have to bemadebetween the available options,
and the treatment should be implemented as quickly as possible. Also,
the prevention or management of potential complications related to
the devices should be considered. As for patient selection, the combina-
tion of NT-proBNP levels N3.500 ng/L and/or levels of the cardiac bio-
marker ST2 N 350 μg/mL is predictive of high mortality rates, reaching
70%–80% during the ﬁrst 24 h and can help to identify patients with
the highest likelihood to beneﬁt from assist devices [12].5. Data on levosimendan
5.1. Pharmacologic rationale for the use of levosimendan
The inodilator levosimendan offers potential beneﬁts in the setting
of AHF/CS complicating ACS. Levosimendan has been developed for
the treatment of AHF and other cardiac conditions where the use of an
inodilator is considered appropriate. At least three major pharmacolog-
ical actions have been identiﬁed [4], i.e. (i) the selective binding to
Ca2+-saturated cardiac troponin C, (ii) the opening of ATP-sensitive
potassium (KATP) channels in the vasculature, and (iii) the opening of
KATP channels in the mitochondria. The pharmacology of levosimendan
includes positive inotropy with energy-sparing effects, positive effects
on ventriculo-arterial coupling, peripheral vasodilation and increasing
tissue perfusion, anti-stunning effects and anti-inﬂammatory effects [4].
As opposed to other inotropic drugs used in HF treatment,
levosimendan does not raise intracellular calcium levels [29]. This im-
plies that less energy is utilized by the cardiomyocytes, because re-in-
ternalization of calcium increases ATP expenditure and accounts for
30% of the energy consumed by the cardiomyocyte during the contrac-
tion–relaxation cycle. A comparison of levosimendan and milrinone
[30] shows that both molecules intensify cardiac contraction, but
while milrinone increases oxygen consumption, levosimendan does
not. In clinical settings, levosimendan was also shown to be superior
to dobutamine as it regards myocardial efﬁciency [31,32].
Levosimendan-mediated opening of KATP channels on smooth mus-
cle cells in the vasculature has been demonstrated in many different
vessels. According to another comparison of levosimendan and
milrinone [33], levosimendan improves the microcirculation in the
splanchnic vessels, whereas milrinone has a neutral effect, even though
both drugs have a similar inﬂuence on systemic blood pressure. Further,
levosimendan improved long-term renal function in patients with ad-
vanced chronic HF awaiting cardiac transplantation [34], possibly via
enhanced renal blood ﬂow. Both creatinine levels and creatinine clear-
ance were improved as compared to controls.
In another study, Bragadottir et al. [35] showed that levosimendan
had positive effects on renal blood ﬂow, glomerular ﬁltration rate, renal
oxygen consumption and oxygenation. The authors found a remarkable
difference between levosimendan and dopamine regarding glomerular
ﬁltration rates [36]. A possible explanation for this is that levosimendan
has differential effects on afferent and efferent vessels in the kidney,
whereas the effects of dopamine are independent of the vessel type [37].
Opening of KATP channels in the cardiac mitochondria is assumed to
exert cardioprotective effects [38]. Du Toit et al. [39] showed that in a
guinea pig model, preconditioning with levosimendan decreased the
extent of hypoxic myocardial injury from 100% to 10%. Also, post-
conditioning activity of levosimendan was demonstrated by Hönisch
et al. [40]. The use of levosimendan after an ischemic event can diminish
stunning. According to Sonntag et al. [41], patients with ACS treated
with levosimendan experienced a decrease in the total number of
hypokinetic segments as compared to placebo. Levosimendan reduces
myocardial infarct size and increases left-ventricular function after
acute coronary occlusion [42]. Additionally, in animal models
levosimendan showed anti-ischemic [43], anti-remodeling [44] and
anti-apoptotic effects [45]. As it regards effects on neurohormones, in
the SURVIVE study levosimendan was superior to dobutamine for a
sustained decrease of BNP [46].
5.2. Levosimendan in the treatment of AHF complicating ACS
In the placebo-controlled RUSSLAN trial [7], 6-h infusions of
levosimendan at different doses were shown to be safe in 504 patients,
who developed HF within 5 days after AMI and required inotropic ther-
apy due to symptomatic HF despite conventional therapy. Levosimendan
decreased the incidence of worsening heart failure and reduced both
short-term and long-termmortality (Fig. 2). Hypotension, as a side effect
Fig. 2. RUSSLAN trial: overall survival during 180 days after infusion of levosimendan or
placebo. Adapted from Moiseyev et al. [7].
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and use of a bolus. Other adverse events, such as episodes of ischemia,
ventricular extra-systoles, and sinus tachycardia, occurred mainly or ex-
clusively at higher doses. The lower levosimendandoses of 0.1 μg/kg/min
and 0.2 μg/kg/min were accompanied by a low risk of adverse events.
In their placebo-controlled trial, Sonntag et al. [41] evaluated 24 pa-
tients with ACS. Levosimendan was administered as a bolus (24 μg/kg)
for 10 min after PCI. This treatment induced reductions in the number
of hypokinetic segments in the left ventricle and increased LVEF, sug-
gesting that levosimendan may counteract post-ischemic stunning. In
addition, pulmonary arterial pressure decreased in the levosimendan
group, but not in the placebo group.
De Luca et al. [47] investigated levosimendan as compared to place-
bo in 26 patients with STEMI and left-ventricular dysfunction (EF
b40%). Levosimendan was applied at a bolus dose of 12 μg/kg 10 min
after PCI, followed by an infusion at 0.1 μg/kg/min for 24 h. As compared
with placebo, levosimendan was associated with improved coronary
ﬂow reserve, reduced pulmonary capillary wedge pressure, and in-
creased CI. Another study by the same group [48] was conducted in 52
patients with anterior STEMI. Again, they were treated with
levosimendan at a bolus dose of 12 μg/kg for10 min after PCI, followed
by an infusion at 0.1 μg/kg/min for 24 h. Levosimendan improved
isovolumetric relaxation as compared to placebo, and reduced the
ratio of peak early to late diastolic ﬂow velocities, indicating decreased
ﬁlling pressure.
Sixty-one patients who developed clinical signs of HF (including CS)
within 48 h after primary PCI-treated STEMI were included in the trial
by Husebye et al. [49]. The treatment consisted of levosimendan at a
dose of 0.2 μg/kg/min for 60 min followed by 0.1 μg/kg/min for 24 h,
or placebo. The infusions were started approximately 24 h after PCI.
Evaluation of the primary endpoint, which was deﬁned as the change
in wall motion score index after 5 days, by echocardiography, showed
that levosimendan improved contractility in post-ischemic myocardi-
um compared to placebo (p = 0.031). Numerically fewer patients
died or were re-hospitalized for HF, even though this difference was
not statistically signiﬁcant. Hypotension occurred more frequently
with levosimendan (67% vs. 36%; p = 0.029).
In the randomized, placebo-controlled, open-label study byWu et al.
[50], 30 patients with severe HF (NYHA III–IV) and LVEF b40% after PCI-
treatedAMI received either levosimendan as an infusion at 0.1 μg/kg/min
for 24 h, or placebo. Low-dose dobutamine echocardiography showed
signiﬁcantly less stunned and infarcted segments in levosimendan
group than with placebo.
Another randomized, placebo-controlled trial [51] enrolled 160 pa-
tientswith HF due to AMI, whowere treatedwith orwithout revascular-
ization. Levosimendan was administered as a bolus at a dose of 24 μg/kg
in 10min followed by an infusion at 0.1 μg/kg/min for 24 h. As compared
to placebo, this treatment induced signiﬁcant improvement in the pri-
mary endpoint, which was a composite outcome including death andworsening heart failure at six months (43.7% vs. 62.5%; HR, 0.636; p =
0.041).
Indeed the largest head to head comparison of levosimendan vs. do-
butamine in AHF related to AMI remains the SURVIVE clinical trial. This
randomized, double-blind trial compared the efﬁcacy and safety of in-
travenous levosimendan or dobutamine in 1327 patients hospitalized
with acute decompensated heart failurewho required inotropic support
[52]. A relevant number of patients were hospitalizedwith AMI (178, or
13.4%) and the data of mortality were stratiﬁed also for this parameter.
The 31-day mortality in the AHF-AMI subgroup was 23/83 (28%) and
30/95 (32%) in the levosimendan and dobutamine arms respectively
(RR 0.83 [0.48–1.43]). As a comparison, the 31-day mortality in the
non-AHF-AMI subgroup was 56/581 (10%) and 61/568 (11%) in the
levosimendan and dobutamine arms respectively (RR 0.89 [0.62–1.28]).
Two independent meta-analyses by Landoni et al. [53] and Koster
et al. [54], considering 45 and 48 randomized studies respectively, fo-
cused also on the adverse effects of levosimendan vs. comparator
arms (active drugs or placebo on top of standard of care). With the ex-
ception of hypotension, no other signs for increase of adverse events by
levosimendan were reported in either meta-analyses.
5.3. Levosimendan in the treatment of CS complicating ACS
In their randomized, prospective, single-center, open-label trial,
Fuhrmann et al. [55] found that levosimendan appeared superior to
enoximone as an add-on therapy in refractory CS complicating AMI.
Thirty-two patients received levosimendan (a bolus at 12 μg/kg/10 min
followed by an infusion at 0.1 μg/kg/min for 50 min and 0.2 μg/kg/min
for 23 h) or enoximone on top of the current treatment (PCI, vasopres-
sors, etc.). Both drugs had similar hemodynamic effects, but the survival
at 30 days was signiﬁcantly in favor of levosimendan (69% vs. 37%; p =
0.023). Death from multiple organ failure occurred only in the
enoximone group. The levosimendan-treated arm tended to require
less additive dobutamine and norepinephrine treatment than the
enoximone group to maintain tissue perfusion.
Twenty-two STEMI patientswith CS after PCI were enrolled in a ran-
domized, prospective, single-center, open-label trial [56] comparing
levosimendan (a bolus dose of 24 μg/kg over 10 min followed by an in-
fusion at 0.1 μg/kg/min/24 h) and dobutamine (5 μg kg−1 min−1, with-
out loading dose) in addition to current standard therapy. Treatment
effects on CI and cardiac power index were consistently better with
levosimendan than with dobutamine. Signiﬁcant reductions in
isovolumetric relaxation time and increases in the early diastolic/late di-
astolic ﬂow ratio occurred in the levosimendan group at 24 h [57], and
the LVEF was signiﬁcantly improved (p = 0.003) [58]. No difference
was seen regarding long-term survival.
In their observational study, Russ et al. [59] treated 56 patients with
myocardial infarction and persisting CS 24 h after percutaneous revas-
cularization with levosimendan 12 μg/kg for 10 min followed by 0.05–
0.2 μg/kg/min for 24 h. Norepinephrine and dobutamine therapy only
resulted in marginal improvements in CI and mean arterial pressure,
while levosimendan produced signiﬁcant increases in CI (p b 0.01)
and cardiac power index (p b 0.01). At the same time, systemic vascular
resistance decreased signiﬁcantly (p b 0.01).
A non-randomized trial [60] compared supplementary levosimendan
treatment with intra-aortic balloon pump placement in patients with
AMI and refractory CS following preliminary hemodynamic support (do-
butamine with or without norepinephrine) and primary PCI. Infusion of
levosimendan resulted in early and sustained hemodynamic improve-
ment. CI and cardiac power index rosemore rapidly in the levosimendan
arm, and systemic vascular resistance showed amore pronounced initial
decrease. For mean arterial pressure, there were no differences between
the two treatments. This also applied to the use of supplementary drugs
(dobutamine and norepinephrine).
Data from 94 consecutive patients with CS due to STEMI [61] that
were obtained prospectively in two Swedish registries suggest that
155M.S. Nieminen et al. / International Journal of Cardiology 218 (2016) 150–157the use of levosimendan neither increases nor decreases mortality.
Moreover, there were no differences in adverse events or length of
hospital stay between patients who received levosimendan and those
who did not.
Another potential indication of levosimendan therapy is transient left
ventricular apical ballooning syndrome (Takotsubo cardiomyopathy). In
an animal model mimicking Takotsubo syndrome [62], levosimendan
was shown to reverse adrenaline-induced apical dysfunction. In a case
series comprising 13 consecutive patients with Takotsubo cardiomyopa-
thy, Santoro et al. [63] found that the use of levosimendanwas associated
with signiﬁcantly improved left-ventricular function. The introduction of
levosimendan rapidly provided relief of signs and symptoms of HF. Sim-
ilarly, in isolated RV cardiogenic shock patients levosimendan showed
profound hemodynamic improvement [64].
Overall, the existing studies on levosimendan in AHF and CS are not
adequately powered for reaching conclusions on the effect of the
treatment on survival. As reviewed, however, the existing data on the
beneﬁcial activity of levosimendan treatment can justify its use in
certain AHF settings and in CS also when related to ACS.
6. Panel's recommendations on the use of levosimendan in AHF/CS
complicating ACS
6.1. Indication
Based on the available evidence, levosimendan should be considered
in the setting of AHF/CS complicating ACS according to the clinical mani-
festations. The four Killip classes were considered as a starting point for
the discussion, but class I was omitted since it includes individuals with
no clinical signs of heart failure. The patients in the remaining three clas-
ses were further segmented in four types (see Table 1). The table details
the suggested drug treatment in each of these types after initial therapy,
including recommendations on the use of levosimendan. Overall, while
levosimendan could convey beneﬁts in patients with SBP N 110 only
when β-blocker is used, and urinary output is insufﬁcient after diuretics,
it is a rationale option when SBP is between 85 and 110 mm Hg, and
should be a drug of choice in CS, usually combined with norepinephrine.
Levosimendan can either replace other inotropic drugs, or can be
used in combination with other inotropic and vasopressor agents. Once
the patient's cardiac function improves, weaning off the co-medication
is possible. Finally, it is also important to prefer levosimendan over
adrenergic inotropes as a ﬁrst line therapy for all ACS-AHF patientsTable 1
Medical treatment options in patients with AHF/CS and ACS after initial therapiesa.
Killip class II, rales, pulmonary congestion
AHF/CS,
segmentation by
SBP
SBP N 110 mm Hg 85 b SBP b 110 mm Hg,
worsening of HF
Loop diuretic (e.g.
furosemide i.v.)
+ +
β-blocker maintain reduce or withdraw
according to patient statusb
Vasodilator (e.g. nitrate) + + initially
Inotrope i.v. (e.g.
dobutamine)
− + initially
Vasopressor i.v. (e.g.
norepinephrine)
− − not initially
Inodilator i.v.
levosimendan
−/+ (when β-blocker is used
and urinary output is
insufﬁcient after diuretics)
−/+ (when β-blocker is used
and urinary output is
insufﬁcient after diuretics)
ECMO, LVAD, (IABPc) − −
AHF, acute heart failure; CS, cardiogenic shock; ACS, acute coronary syndrome; SBP, systolic blo
tion; LVAD, left ventricular assist device; CI, cardiac index.
a Monitoring, ﬂuid challenge, arrhythmia care, cardiac catheter including angiography/Percu
b Some patients in this class need beta-blockade despite hemodynamic impairment, to man
c IABP is indeed not recommended by the most recent STEMI ESC guidelines but in case of mwho are taking beta-receptor blockers chronically and/or when urinary
output is insufﬁcient after diuretics.
6.2. Dosing
In the settingof AHF/CS,we recommenddoses of 0.05–0.1 μg/kg/min
for 24 h. If a faster onset of action is needed, an infusion of 0.2 μg/kg/min
could be used during the ﬁrst 60 min. Risk–beneﬁt proﬁle with
0.2 μg/kg/min dose is shown to be favorable with up to 6-h infusion.
Application of a bolus dose should be avoided due to the risk of
hypotension.
6.3. Monitoring
Hypotension, a well-known side effect of levosimendan, is of partic-
ular concern in patients with ACS. Therefore, continuous hemodynamic
monitoring is of major importance. This includes ECG, blood pressure,
SaO2, heart rate, urinary output, potassium levels, and clinical signs.
End-organ function (liver, kidney, mental status) should be evaluated.
Central venous and arterial catheter measurements are required in CS.
Furthermore, a pulmonary artery catheter offers a complete hemody-
namic assessment and monitoring of mixed venous saturation reﬂects
general tissue oxygenation in complicated cases, and is recommended
to be used in cardiogenic shock to monitor ﬁlling pressures and output.
Also, CO can be assessed non-invasively using echocardiography.
As a general rule, we feel that the use of levosimendan should
preferable reside with experienced physicians.
7. Conclusions
On the basis of the existing literature and the direct clinical experi-
ence, themembers of the panel agree that (i) the inodilator levosimendan
offers potential beneﬁts in treatment of acute heart failure and/or cardio-
genic shock complicating ACS due to a range of distinct effects including
positive inotropy, restauration of ventriculo-arterial coupling, increases
in tissue perfusion, and anti-stunning and anti-inﬂammatory effects;
(ii) clinical trials investigating levosimendan in acute heart failure and
cardiogenic shock suggest improvements in cardiac function, hemody-
namics, and end-organ function. Re-hospitalization rates are decreased,
(iii) adverse effects are generally less common with levosimendan than
with other inotropes, inodilators or inoconstrictors, (iv) the indication of
levosimendan depends on the presence of congestion, levels ofIII, acute pulmonary oedema IV, hypotension or CS
85 b SBP b 110 mm Hg, decreasing SBP b; 85 mm Hg, evidence of
peripheral vasoconstriction
+ +
withdrawb withdraw
+ initially −
+ in case of poor response to
standard therapy
+ initially
− not initially + (aiming for SBP N 90 mm Hg,
with inotrope or inodilator)
+ (when SBP N 90 mm Hg, if
hypotensive response, consider
ﬁlling or combining vasopressor)
+ (with vasopressor)
− + (with CI b 1.8 L/min and not
responding to medical treatment)
od pressure; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygena-
taneous Coronary Intervention (PCI).
age ventricular arrhythmias, or to rate control AF.
echanical complication.
156 M.S. Nieminen et al. / International Journal of Cardiology 218 (2016) 150–157blood pressure and heart rate, and the extent of cardiac ischemia,
(v) levosimendan can be used alone or in combinationwith other agents,
but (vi) it requires continuousmonitoring due to the risk of hypotension.
Finally, the panel agrees on the practical recommendations on indication,
dosing, and monitoring as described in chapter 6 of this article.
Author contributions
Three of the authors (M.S.N., M.K., and P.P.) independently
performed the preliminary search for the relevant publications. All of
the authors contributed substantially to discussions of the existing
literature and to the text of the recommendations, and reviewed the
manuscript before submission.
Declaration of interest
This project did not receive any ﬁnancial support, apart for an
unrestricted educational grant by Orion Pharma (Finland) meant to
cover the logistic expenses related to the organization of the consensus
meeting in Munich on Jan. 22, 2016. The attendees were invited by the
chairman M.S.N. on the basis of their clinical experience and scientiﬁc
production, and did not receive any honoraria. P.P. and M.K. are
employees of Orion Pharma.
Acknowledgments
We thank Dr. J. Moser for editing the manuscript.
References
[1] M. Gheorghiade, F. Zannad, G. Sopko, L. Klein, I.L. Piña, M.A. Konstam, et al., Acute
heart failure syndromes: current state and framework for future research, Circula-
tion 112 (25) (2005) 3958–3968.
[2] J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Böhm, K. Dickstein, et al.,
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2012: the task force for the Diagnosis and Treatment of Acute and Chronic Heart
Failure 2012 of the European Society of Cardiology. Developed in collaboration
with the Heart Failure Association (HFA) of the ESC, Eur. Heart J. 33 (14) (2012)
1787–1847.
[3] H. Thiele, E.M. Ohman, S. Desch, I. Eitel, S. de Waha, Management of cardiogenic
shock, Eur. Heart J. 36 (20) (2015) 1223–1230.
[4] Z. Papp, I. Édes, S. Fruhwald, S.G. De Hert, M. Salmenperä, H. Leppikangas, et al.,
Levosimendan: molecular mechanisms and clinical implications: consensus of ex-
perts on the mechanisms of action of levosimendan, Int. J. Cardiol. 159 (2) (2012)
82–87.
[5] M.S. Nieminen, S. Fruhwald, L.M. Heunks, P.K. Suominen, A.C. Gordon, M. Kivikko,
et al., Levosimendan: current data, clinical use and future development, Heart
Lung Vessel 5 (4) (2013) 227–245.
[6] P. Pollesello, J. Parissis, M. Kivikko, V.P. Harjola, Levosimendan meta-analyses: is
there a pattern in the effect on mortality? Int. J. Cardiol. 209 (2016) 77–83.
[7] V.S. Moiseyev, P. Põder, N. Andrejevs, M.Y. Ruda, A.P. Golikov, L.B. Lazebnik, et al.,
Safety and efﬁcacy of a novel calcium sensitizer, levosimendan, in patients with
left ventricular failure due to an acute myocardial infarction. A randomized,
placebo-controlled, double-blind study (RUSSLAN), Eur. Heart J. 23 (18) (2002)
1422–1432.
[8] S.G. Priori, W. Klein, J.P. Bassand, et al., Medical Practice Guidelines. Separating sci-
ence from economics, Eur. Heart J. 24 (21) (2003) 1962–1964.
[9] M.S. Nieminen, D. Brutsaert, K. Dickstein, H. Drexler, F. Follath, V.-P. Harjola, et al.,
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure
patients: description of population, Eur. Heart J. 27 (22) (2006) 2725–2736.
[10] T. Tarvasmäki, V.P. Harjola, M.S. Nieminen, K. Siirilä-Waris, J. Tolonen, H. Tolppanen,
et al., Acute heart failure with and without concomitant acute coronary syndromes:
patients characteristics, management, and survival, J. Card. Fail. 20 (2014) 723–730.
[11] L. Desta, T. Jernberg, I. Löfman, C. Hofman-Bang, I. Hagerman, J. Spaak, et al., Inci-
dence, temporal trends, and prognostic impact of heart failure complicating acute
myocardial infarction. The SWEDEHEART Registry (Swedish Web-System for En-
hancement and Development of Evidence-Based Care in Heart Disease Evaluated
According to Recommended therapies): a study of 199,851 patients admitted with
index acute myocardial infarctions, 1996 to 2008, JACC Heart Fail. 3 (3) (2015)
234–242.
[12] V.P. Harjola, J. Lassus, A. Sionis, L. Køber, T. Tarvasmäki, J. Spinar, et al., Clinical pic-
ture and risk prediction of short-term mortality in cardiogenic shock, Eur. J. Heart
Fail. 17 (5) (2015) 501–509.
[13] L. De Luca, Z. Olivari, A. Farina, L. Gonzini, D. Lucci, A. Di Chiara, et al., Temporal
trends in the epidemiology, management, and outcome of patients with cardiogenicshock complicating acute coronary syndromes, Eur. J. Heart Fail. 17 (11) (2015)
1124–1132.
[14] R.V. Jeger, D. Radovanovic, P.R. Hunziker, M.E. Pﬁsterer, J.C. Stauffer, P. Erne, et al.,
Ten-year trends in the incidence and treatment of cardiogenic shock, Ann. Intern.
Med. 149 (9) (2008) 618–626.
[15] D. Kolte, S. Khera, K.C. Dabhadkar, S. Agarwal, W.S. Aronow, R. Timmermans, et al.,
Trends in coronary angiography, revascularization, and outcomes of cardiogenic
shock complicating non-ST-elevation myocardial infarction, Am. J. Cardiol. 117
(2016) 1–9.
[16] A. Mebazaa, H. Tolppanen, C. Mueller, J. Lassus, S. DiSomma, G. Baksyte, et al., Acute
heart failure and cardiogenic shock: a multidisciplinary practical guidance, Intensive
Care Med. 42 (2) (2016) 147–163.
[17] J. López-Sendón, E. López de Sá, Acute Heart Failure, in: J. López-Sendón, E. López
(Eds.), Acute Heart Failure in the Setting of Acute Coronary Syndromes, Springer,
London 2008, pp. 168–182.
[18] F. Di Lisa, Mitochondrial contribution in the progression of cardiac ischemic injury,
IUBMB Life 52 (3–5) (2001) 255–261.
[19] J.S. Forrester, G.A. Diamond, H.J. Swan, Correlative classiﬁcation of clinical and he-
modynamic function after acute myocardial infarction, Am. J. Cardiol. 39 (2)
(1977) 137–145.
[20] J.S. Hochman, Cardiogenic shock complicating acute myocardial infarction:
expanding the paradigm, Circulation 107 (24) (2003) 2998–3002.
[21] J.D. Chantler, E.G. Lakatta, S.S. Najjar, Arterial–ventricular coupling: mechanistic in-
sights into cardiovascular performance at rest and during exercise, J. Appl. Physiol.
105 (4) (1985) 1342–1351 (2008).
[22] J.A. Chirinos, Ventricular–arterial coupling: invasive and non-invasive assessment,
Arthritis Res. 7 (1) (2013) 2–14.
[23] K. Werdan, M. Ruß, M. Buerke, G. Delle-Karth, A. Geppert, F.A. Schöndube, German
Cardiac Society, German Society of Intensive Care and Emergency Medicine,
German Society for Thoracic and Cardiovascular Surgery, Austrian Society of Inter-
nal and General Intensive Care Medicine, German Interdisciplinary Association of
Intensive Care and Emergency Medicine, Austrian Society of Cardiology; German
Society of Anaesthesiology and Intensive Care Medicine, German Society of Preven-
tive Medicine and Rehabilitation, Cardiogenic shock due to myocardial infarction:
diagnosis, monitoring and treatment: a German–Austria S3 Guideline, Dtsch.
Arztebl. Int. 109 (19) (2012) 343–351.
[24] J. Nativi-Nicolau, C.H. Selzman, J.C. Fang, J. Stehlik, Pharmacologic therapies for acute
cardiogenic shock, Curr. Opin. Cardiol. 29 (3) (2014) 250–257.
[25] S. Unverzagt, L. Wachsmuth, K. Hirsch, H. Thiele, M. Buerke, J. Haerting, et al., Inotro-
pic agents and vasodilator strategies for acute myocardial infarction complicated by
cardiogenic shock or low cardiac output syndrome, Cochrane Database Syst. Rev. 1
(2014), CD009669.
[26] G. Greenberg, E. Cohen, M. Garty, Z. Iakobishvili, A. Sandach, S. Behar, et al., Out-
comes of acute heart failure associated with acute coronary syndrome versus
other causes, Acute Card. Care 13 (2) (2011) 87–92.
[27] R. Pirracchio, J. Parenica, M. Resche Rigon, S. Chevret, J. Spinar, J. Jarkovsky, et al.,
The effectiveness of inodilators in reducing short term mortality among patient with
severe cardiogenic shock: a propensity-based analysis, PLoS One 8 (8) (2013), e71659.
[28] A. Mebazaa, J. Parissis, R. Porcher, E. Gayat, M. Nikolaou, F.V. Boas, et al., Short-term
survival by treatment among patients hospitalized with acute heart failure: the
global ALARM-HF registry using propensity scoring methods, Intensive Care Med.
37 (2) (2011) 290–301.
[29] P. Pollesello, Z. Papp, J.G. Papp, Calcium sensitizers: what have we learned over the
last 25 years? Int. J. Cardiol. 203 (2016) 543–548.
[30] P. Kaheinen, P. Pollesello, J. Levijoki, H. Haikala, Effects of levosimendan and
milrinone on oxygen consumption in isolated guinea-pig heart, J. Cardiovasc.
Pharmacol. 43 (4) (2004) 555–561.
[31] H. Ukkonen, M. Saraste, J. Akkila, M.J. Knuuti, P. Lehikoinen, K. Någren, et al., Myo-
cardial efﬁciency during calcium sensitization with levosimendan: a noninvasive
study with positron emission tomography and echocardiography in healthy volun-
teers, Clin. Pharmacol. Ther. 61 (5) (1997) 596–607.
[32] H. Ukkonen, M. Saraste, J. Akkila, J. Knuuti, M. Karanko, H. Iida, et al., Myocardial ef-
ﬁciency during levosimendan infusion in congestive heart failure, Clin. Pharmacol.
Ther. 68 (5) (2000) 522–531.
[33] P.S. Pagel, D.A. Hettrick, D.C. Warltier, Inﬂuence of levosimendan, pimobendan, and
milrinone on the regional distribution of cardiac output in anaesthetized dogs, Br. J.
Pharmacol. 119 (3) (1996) 609–615.
[34] G. Zemljic, M. Bunc, A.P. Yazdanbakhsh, B. Vrtovec, Levosimendan improves renal
function in patients with advanced chronic heart failure awaiting cardiac transplan-
tation, J. Card. Fail. 13 (6) (2007) 417–421.
[35] G. Bragadottir, B. Redfors, S.E. Ricksten, Effects of levosimendan on glomerular ﬁltra-
tion rate, renal blood ﬂow, and renal oxygenation after cardiac surgery with cardio-
pulmonary bypass: a randomized placebo-controlled study, Crit. Care Med. 41 (10)
(2013) 2328–2335.
[36] B. Redfors, G. Bragadottir, J. Sellgren, K. Swärd, S.E. Ricksten, Dopamine increases
renal oxygenation: a clinical study in post-cardiac surgery patients, Acta
Anaesthesiol. Scand. 54 (2010) 183–190.
[37] M.B. Yilmaz, E. Grossini, J.C. Silva Cardoso, I. Édes, F. Fedele, P. Pollesello, et al., Renal
effects of levosimendan: a consensus report, Cardiovasc. Drugs Ther. 27 (6) (2013)
581–590.
[38] L.V. Zingman, A.E. Alekseev, D.M. Hodgson-Zingman, A. Terzic, ATP-sensitive potas-
sium channels: metabolic sensing and cardioprotection, J. Appl. Physiol. 103 (5)
(1985) 1888–1893 (2007).
[39] E.F. du Toit, A. Genis, L.H. Opie, P. Pollesello, A. Lochner, A role for the RISK pathway
and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the
isolated guinea pig heart, Br. J. Pharmacol. 154 (1) (2008) 41–50.
157M.S. Nieminen et al. / International Journal of Cardiology 218 (2016) 150–157[40] A. Hönisch, N. Theuring, B. Ebner, C. Wagner, R.H. Strasser, C. Weinbrenner,
Postconditioning with levosimendan reduces the infarct size involving the PI3K
pathway and KATP-channel activation but is independent of PDE-III inhibition,
Basic Res. Cardiol. 105 (2) (2010) 155–167.
[41] S. Sonntag, S. Sundberg, L.A. Lehtonen, F.X. Kleber, The calcium sensitizer
levosimendan improves the function of stunned myocardium after percutaneous
transluminal coronary angioplasty in acute myocardial ischemia, J. Am. Coll. Cardiol.
43 (12) (2004) 2177–2182.
[42] M. Tarkia, C. Stark, M. Haavisto, R. Kentala, T. Vähäsilta, T. Savunen, et al., Effect of
levosimendan therapy on myocardial infarct size and left ventricular function
after acute coronary occlusion, Heart 102 (6) (2016) 465–471.
[43] J. Levijoki, P. Pollesello, P. Kaheinen, H. Haikala, Improved survival with simendan
after experimental myocardial infarction in rats, Eur. J. Pharmacol. 419 (2–3)
(2001) 243–248.
[44] M. Louhelainen, E. Vahtola, P. Kaheinen, H. Leskinen, S. Merasto, V. Kytö, et al.,
Effects of levosimendan on cardiac remodelling and cardiomyocyte apoptosis in hy-
pertensive Dahl/Rapp rats, Br. J. Pharmacol. 150 (7) (2007) 851–861.
[45] M. Maytin, W.S. Colucci, Cardioprotection: a new paradigm in the management of
acute heart failure syndromes, Am. J. Cardiol. 96 (6 A) (2005) 26G–31G.
[46] A. Cohen-Solal, D. Logeart, B. Huang, D. Cai, M.S. Nieminen, A. Mebazaa, Lowered
B-type natriuretic peptide in response to levosimendan or dobutamine treatment
is associatedwith improved survival in patients with severe acutely decompensated
heart failure, J. Am. Coll. Cardiol. 53 (2009) 2343–2348.
[47] L. De Luca, P. Proietti, A. Celotto, C. Bucciarelli-Ducci, G. Benedetti, A. Di Roma, et al.,
Levosimendan improves hemodynamics and coronary ﬂow reserve after percutane-
ous coronary intervention in patients with acute myocardial infarction and left ven-
tricular dysfunction, Am. Heart J. 150 (3) (2005) 563–568.
[48] L. De Luca, G. Sardella, P. Proietti, A. Battagliese, G. Benedetti, A. Di Roma, et al., Ef-
fects of levosimendan on left ventricular diastolic function after primary angioplasty
for acute anterior myocardial infarction: a Doppler echocardiographic study, J. Am.
Soc. Echocardiogr. 19 (2) (2006) 172–177.
[49] T. Husebye, J. Eritsland, C. Müller, L. Sandvik, H. Arnesen, I. Seljeﬂot, et al.,
Levosimendan in acute heart failure following primary percutaneous coronary
intervention-treated acute ST-elevation myocardial infarction. Results from the
LEAF trial: a randomized, placebo-controlled study, Eur. J. Heart Fail. 15 (5)
(2013) 565–572.
[50] X. Wu, J. Wu, X. Yan, Y. Zhang, Enhancement of myocardial function and reduction
of injury with levosimendan after percutaneous coronary intervention for acute
myocardial infarction: a pilot study, Cardiology 128 (2) (2014) 202–208.
[51] Z. Jia, M. Guo, Y.Q. Zhang, H.Q. Liang, L.Y. Zhang, Y. Song, Efﬁcacy of intravenous
levosimendan in patients with heart failure complicated by acutemyocardial infarc-
tion, Cardiology 128 (2014) 195–201.
[52] A. Mebazaa, M.S. Nieminen, M. Packer, A. Cohen-Solal, F.X. Kleber, S.J. Pocock, et al.,
Levosimendan vs dobutamine for patients with acute decompensated heart failure:
the SURVIVE Randomized Trial, JAMA 297 (17) (2007) 1883–1891.[53] G. Landoni, G. Biondi-Zoccai, M. Greco, T. Greco, E. Bignami, A. Morelli, et al., Effects
of levosimendan on mortality and hospitalization. A meta-analysis of randomized
controlled studies, Crit. Care Med. 40 (2) (2012) 634–646.
[54] G. Koster, J. Wetterslev, C. Gluud, J.G. Zijlstra, T.W. Scheeren, I.C. van der Horst, et al.,
Effects of levosimendan for low cardiac output syndrome in critically ill patients:
systematic review with meta-analysis and trial sequential analysis, Intensive Care
Med. 41 (2) (2015) 203–221.
[55] J.T. Fuhrmann, A. Schmeisser, M.R. Schulze, C. Wunderlich, S.P. Schoen, T. Rauwolf,
et al., Levosimendan is superior to enoximone in refractory cardiogenic shock com-
plicating acute myocardial infarction, Crit. Care Med. 36 (8) (2008) 2257–2266.
[56] M.J. García-Gonzáles, A. Domínguez-Rodríguez, J.J. Ferrer-Hita, P. Abreu-González,
M.B. Muñoz, Cardiogenic shock after primary percutaneous coronary intervention:
effects of levosimendan compared with dobutamine on haemodynamics, Eur. J.
Heart Fail. 8 (7) (2006) 723–728.
[57] A. Dominguez-Rodriguez, S. Samimi-Fard, M.J. Garcia-Gonzalez, P. Abreu-Gonzalez,
Effects of levosimendan versus dobutamine on left ventricular diastolic function in
patients with cardiogenic shock after primary angioplasty, Int. J. Cardiol. 128 (2)
(2008) 214–217.
[58] S. Samimi-Fard, M.J. García-González, A. Domínguez-Rodríguez, P. Abreu-González,
Effects of levosimendan versus dobutamine on long-term survival of patients with
cardiogenic shock after primary coronary angioplasty, Int. J. Cardiol. 127 (2)
(2008) 284–287.
[59] M.A. Russ, R. Prondzinsky, A. Christoph, A. Schlitt, U. Buerke, G. Söffker, et al., Hemo-
dynamic improvement following levosimendan treatment in patients with acute
myocardial infarction and cardiogenic shock, Crit. Care Med. 12 (2007) 2732–2739.
[60] A. Christoph, R. Prondzinsky, M. Russ, M. Janusch, A. Schlitt, H. Lemm, et al., Early
and sustained haemodynamic improvement with levosimendan compared to
intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating
acute myocardial infarction, Acute Card. Care 10 (1) (2008) 49–57.
[61] E. Omerovic, T. Råmunddal, P. Albertsson, M. Holmberg, P. Hallgren, J. Boren, et al.,
Levosimendan neither improves nor worsens mortality in patients with cardiogenic
shock due to ST-elevation myocardial infarction, Varsc. Health Risk Manag. 6 (2010)
657–663.
[62] H. Paur, P.T. Wright, M.B. Sikkel, M.H. Tranter, C. Mansﬁeld, P. O'Gara, et al., High
levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic
receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy, Circu-
lation 126 (6) (2002) 697–706.
[63] F. Santoro, R. Ieva, A. Ferraretti, V. Ienco, G. Carpagnano, M. Lodispoto, et al., Safety
and feasibility of levosimendan administration in takotsubo cardiomyopathy: a
case series, Cardiovasc. Ther. 31 (6) (2013) e133–e137.
[64] M.A. Russ, R. Prondzinsky, J.M. Carter, A. Schlitt, H. Ebelt, H. Schmidt, et al., Right
ventricular function in myocardial infarction complicated by cardiogenic shock: im-
provement with levosimendan, Crit. Care Med. 37 (2009) 3017–3023.
